APA

Usmani S. Z., Cavenagh J. D., Belch A. R., Hulin C., Basu S., White D., Nooka A., Ervin-Haynes A., Yiu W., Nagarwala Y., Berger A., Pelligra C. G., Guo S., Binder G., Gibson C. J. & Facon T. (20161216). Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma. : Journal of medical economics.

Chicago

Usmani S Z, Cavenagh J D, Belch A R, Hulin C, Basu S, White D, Nooka A, Ervin-Haynes A, Yiu W, Nagarwala Y, Berger A, Pelligra C G, Guo S, Binder G, Gibson C J and Facon T. 20161216. Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma. : Journal of medical economics.

Harvard

Usmani S. Z., Cavenagh J. D., Belch A. R., Hulin C., Basu S., White D., Nooka A., Ervin-Haynes A., Yiu W., Nagarwala Y., Berger A., Pelligra C. G., Guo S., Binder G., Gibson C. J. and Facon T. (20161216). Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma. : Journal of medical economics.

MLA

Usmani S Z, Cavenagh J D, Belch A R, Hulin C, Basu S, White D, Nooka A, Ervin-Haynes A, Yiu W, Nagarwala Y, Berger A, Pelligra C G, Guo S, Binder G, Gibson C J and Facon T. Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma. : Journal of medical economics. 20161216.